Case in point, we've spotted 2 warning signs for Kronos Bio you should be aware of, and 1 of them is significant. Have ...
Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial ...
Bank of New York Mellon Corp reduced its stake in Kronos Worldwide, Inc. (NYSE:KRO – Free Report) by 23.2% during the fourth ...
Kronos Worldwide has a 1 year low of $7.17 and a 1 year high of $14.50. The stock has a market capitalization of $899.01 million, a price-to-earnings ratio of 9.65 and a beta of 1.16. Get Kronos ...
Zacks Investment Research on MSN13d
Kronos Worldwide's Earnings and Revenues Lag Estimates in Q4Kronos Worldwide, Inc. KRO reported fourth-quarter 2024 loss of 12 cents per share, wider than a loss of 5 cents per share a ...
Los Angeles, CA, March 12, 2025 (GLOBE NEWSWIRE) -- Los Angeles, CA – March 12, 2025 – Atomiq Inc., a subsidiary of Kronos Advanced Technologies, Inc. (OTC: KNOS), proudly announces that the ...
Pre-application engagement of the Kronos MMR continues through collaboration with the University of Illinois ...
SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth ...
"The USPTO allowance of this patent highlights Atomiq's dedication to pioneering sustainable and transformative energy solutions," said Greg Rubin, CEO of Kronos Advanced Technologies. "Following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback